Nonclinical Safety Assessment of CFZ533, a Fc-Silent Anti-CD40 Antibody, in Cynomolgus Monkeys
Author:
Affiliation:
1. Preclinical Safety
2. Pharmacokinetic Sciences
3. Autoimmunity/Transplantation/Inflammation Research, Novartis Institutes for Biomedical Research, Novartis Campus, Basel CH 4002, Switzerland
Publisher
Oxford University Press (OUP)
Subject
Toxicology
Link
http://academic.oup.com/toxsci/advance-article-pdf/doi/10.1093/toxsci/kfy196/25737623/kfy196.pdf
Reference49 articles.
1. A human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys: induction and maintenance therapy;Aoyagi;Am. J. Transpl,2009
2. CD40-CD40 ligand interaction activates proinflammatory pathways in pancreatic islets;Barbe-Tuana;Diabetes,2006
3. A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma;Bensinger;Br. J. Haematol,2012
4. The CD40-CD154 interaction in B cell-T cell liaisons;Bishop;Cytokine Growth Factor Rev,2003
5. TRAF proteins in CD40 signaling;Bishop;Adv. Exp. Med. Biol,2007
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Differential induction of donor-reactive Foxp3+ regulatory T cell via blockade of CD154 vs CD40;American Journal of Transplantation;2024-08
2. Iscalimab Combined With Transient Tesidolumab Prolongs Survival in Pig‐to‐Rhesus Monkey Renal Xenografts;Xenotransplantation;2024-07
3. Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study;Journal of Clinical Neuroscience;2024-01
4. First-in-Human Phase 1 Randomized Trial with the Anti-CD40 Monoclonal Antibody KPL-404: Safety, Tolerability, Receptor Occupancy, and Suppression of T-Cell–Dependent Antibody Response;Journal of Pharmacology and Experimental Therapeutics;2023-09-12
5. Single-cell transcriptomic analysis of renal allograft rejection reveals insights into intragraft TCR clonality;Journal of Clinical Investigation;2023-07-17
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3